Literature DB >> 23440699

Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.

Michael Mühle1, Kerstin Hoffmann, Martin Löchelt, Joachim Denner.   

Abstract

The induction of 2F5- and 4E10-like antibodies broadly neutralising HIV-1 and targeting the membrane external proximal region (MPER) of the transmembrane envelope protein gp41 would be a major advancement for the development of a preventive HIV-1 vaccine, but successful attempts remain rare. Recent studies demonstrated that broadly reactive antibodies develop relatively late during infection and after intensive affinity maturation. Therefore, a prolonged antigen delivery might be beneficial to induce them. Replicating foamy viruses which are characterised by apathogenic but persistent infection could represent suitable carrier viruses for this purpose. In order to develop such a system, we modified the accessory foamy virus Bet protein to contain the MPER of gp41, or the MPER linked to the stabilising fusion peptide proximal region of gp41 and analysed here the antigenic and immunogenic properties of such hybrid proteins. The antigens, expressed and purified to homogeneity, were recognised by the monoclonal antibodies 2F5 and 4E10 with nanomolar affinities and induced high levels of antibodies specific to gp41 after immunisation of rats. The antisera also bound to virus particles attached to infected cells, and peptide-based epitope mapping showed that they recognised the 2F5 epitope. Although no HIV-1 neutralising activity was observed, the presented data demonstrate that using the foamy virus Bet for HIV-1 epitope delivery is successfully applicable. Together with the attractive potential for sustained antigen expression after transfer to replicating virus, these results should therefore provide a first basis for the development of chimeric foamy viruses as novel HIV-1 vaccine vectors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440699     DOI: 10.1007/s12026-013-8387-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  72 in total

1.  AIDS/HIV. A boost for HIV vaccine design.

Authors:  Dennis R Burton; Robin A Weiss
Journal:  Science       Date:  2010-08-13       Impact factor: 47.728

2.  Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats.

Authors:  Fabian Romen; Michael Pawlita; Peter Sehr; Silke Bachmann; Johannes Schröder; Hans Lutz; Martin Löchelt
Journal:  Virology       Date:  2005-11-16       Impact factor: 3.616

3.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

Review 4.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  Intra- and intercellular trafficking of the foamy virus auxiliary bet protein.

Authors:  Charles-Henri Lecellier; Wim Vermeulen; Françoise Bachelerie; Marie-Lou Giron; Ali Saïb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Construction of infectious feline foamy virus genomes: cat antisera do not cross-neutralize feline foamy virus chimera with serotype-specific Env sequences.

Authors:  M Zemba; A Alke; J Bodem; I G Winkler; R L Flower; K Pfrepper; H Delius; R M Flügel; M Löchelt
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

7.  Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response.

Authors:  Jason Ho; Robert A Uger; Michael B Zwick; Mark A Luscher; Brian H Barber; Kelly S MacDonald
Journal:  Vaccine       Date:  2005-02-18       Impact factor: 3.641

Review 8.  Progress and prospects: foamy virus vectors enter a new age.

Authors:  O Erlwein; M O McClure
Journal:  Gene Ther       Date:  2010-07-15       Impact factor: 5.250

9.  Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.

Authors:  Steve Bryson; Jean-Philippe Julien; David E Isenman; Renate Kunert; Hermann Katinger; Emil F Pai
Journal:  J Mol Biol       Date:  2008-07-27       Impact factor: 5.469

10.  HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.

Authors:  Ji Wang; Pei Tong; Lu Lu; Leilei Zhou; Liling Xu; Shibo Jiang; Ying-hua Chen
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

View more
  5 in total

Review 1.  Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Authors:  Joachim Denner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

2.  The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.

Authors:  Victor G Kramer; Siddappa N Byrareddy
Journal:  Expert Rev Vaccines       Date:  2014-06-26       Impact factor: 5.217

3.  Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.

Authors:  Janet Lei; Wolfram Osen; Adriane Gardyan; Agnes Hotz-Wagenblatt; Guochao Wei; Lutz Gissmann; Stefan Eichmüller; Martin Löchelt
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

Review 4.  Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.

Authors:  Arun K Nalla; Grant D Trobridge
Journal:  Biomedicines       Date:  2016-03-29

Review 5.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.